Udenafil Production Cost Reports

The report provides a detailed analysis essential for establishing an udenafil production plant. It encompasses all critical aspects necessary for udenafil production, including the cost of udenafil production, udenafil plant cost, udenafil production costs, and the overall udenafil production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an udenafil production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Udenafil is a selective phosphodiesterase inhibitor that is used to treat erectile dysfunction (ED) in adult men by relaxing penile blood vessels. It improves nitric oxide effects to increase blood flow during sexual stimulation, enabling firmer and longer-lasting erections. It also finds applications in managing pulmonary arterial hypertension (PAH) by dilating lung blood vessels to reduce pressure. It is utilised in benign prostatic hyperplasia (BPH) or lower urinary tract symptoms (LUTS) through improved smooth muscle relaxation in the prostate and bladder. It shows a rapid onset (peak at 1-1.5 hours) and long half-life (10-12 hours). It supports both on-demand and daily dosing for endothelial rehabilitation post-prostatectomy.

The udenafil market is driven by the rising global cases of erectile dysfunction (ED), especially among ageing populations. The increasing awareness via health campaigns, reduced stigma around sexual health, and demand for long-acting inhibitors contribute to its market growth. The expanding geriatric demographics in Asia-Pacific, growth in pulmonary arterial hypertension applications, and non-invasive oral therapy preferences fuel its market. The improved formulations for better tolerability, regulatory support for market entry, and pharma investments in clinical trials expand its applications. The industrial udenafil procurement is influenced by competitive pricing amid generic entrants, reliable supply chains from Asian manufacturers, and bulk purchasing for hospitals and retail pharmacies. The regulatory compliance for exports, dosage availability and geographic expansion into developing markets impact its sourcing strategies.

Raw Material for Udenafil Production

According to the udenafil production plant project report, the key raw materials used in the production of udenafil include 2-propoxybenzoic acid, thionyl chloride, 4-amino-1-methyl-3-propyl-1H-pyrazole-5-carboxamide, and triethylamine.

Production Process of Udenafil

The extensive udenafil production cost report consists of the following major industrial production process:

1. From 2-propoxybenzoic acid: The production process of Udenafil starts with 2-propoxybenzoic acid. The acid is first converted to the corresponding acyl chloride using thionyl chloride under reflux in dichloromethane. This acyl chloride is then condensed with 4-amino-1-methyl-3-propyl-1H-pyrazole-5-carboxamide in the presence of triethylamine and 4-dimethylaminopyridine in dichloromethane to form the corresponding carboxamide intermediate. The resulting carboxamide is sulfonated with chlorosulfonic acid to generate the benzenesulfonyl chloride derivative. This sulfonyl chloride is reacted with racemic 2-(1-methylpyrrolidin-2-yl)ethylamine in dichloromethane to afford the corresponding sulfonamide intermediate. Finally, the sulfonamide goes through intramolecular cyclisation using potassium tert-butoxide in refluxing tert-butanol to get udenafil as the final product.

Udenafil has the molecular formula of C25H36N6O4S with a molecular weight of 516.7 g/mol.  It appears as a white to pale yellow crystalline powder, showing poor aqueous solubility but favourable solubility in organic solvents such as methanol, chloroform, and acetic acid. It has a melting point of 158-161 degrees Celsius and pKa values of around 6.5 and 12.5. It shows moderate lipophilicity (XLogP3-AA ~5-6) with rapid oral absorption (Tmax 1-1.5 hours) and a long plasma half-life of 11-13 hours, enabling once-daily dosing. It goes through CYP3A4-mediated hepatic metabolism to active metabolites without significant food interactions, supporting its pharmacokinetic profile for erectile dysfunction treatment.